Free Trial
→ Gold Hits New Highs as Global Markets Spiral (From Premier Gold Co) (Ad) Buy TAK Stock  Free TAK Stock Alerts

Takeda Pharmaceutical (TAK) Financials

Takeda Pharmaceutical logo
$15.20 -0.18 (-1.17%)
Closing price 03:59 PM Eastern
Extended Trading
$15.20 0.00 (0.00%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Takeda Pharmaceutical

Annual Income Statements for Takeda Pharmaceutical

This table shows Takeda Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 1,032 1,758 1,214 413 3,399 1,894 2,388 953
Consolidated Net Income / (Loss)		 1,037 1,757 1,213 413 3,401 1,895 2,388 954
Net Income / (Loss) Continuing Operations		 1,037 1,757 1,213 413 3,401 1,895 2,388 954
Total Pre-Tax Income 		1,287 2,044 1,146 -567 3,311 2,492 2,826 349
Total Operating Income		 1,399 2,275 2,135 937 4,604 3,795 3,695 1,416
Total Gross Profit		 10,534 11,992 12,982 20,543 19,919 20,275 20,967 18,761
Total Revenue		 15,550 16,658 18,835 30,712 28,908 29,389 30,339 28,196
Operating Revenue		 15,550 16,658 18,835 30,712 28,908 29,389 30,339 28,196
Total Cost of Revenue		 5,016 4,666 5,853 10,169 8,988 9,114 9,372 9,434
Operating Cost of Revenue		 5,016 4,666 5,853 10,169 8,988 9,114 9,372 9,434
Total Operating Expenses		 9,134 9,717 10,847 19,606 15,316 16,480 17,272 17,346
Selling, General & Admin Expense		 5,558 5,910 6,445 9,002 7,916 7,299 7,513 6,969
Marketing Expense		 1,407 1,149 1,604 4,250 3,814 3,894 4,086 4,312
Research & Development Expense		 2,804 3,062 3,308 4,595 4,121 4,332 4,771 4,827
Other Operating Expenses / (Income)		 -1,289 -1,594 -1,436 -562 -2,875 -355 -192 -128
Impairment Charge		 654 1,191 926 2,321 2,340 1,310 1,094 1,366
Total Other Income / (Expense), net		 -112 -231 -989 -1,504 -1,293 -1,303 -869 -1,067
Interest Expense		 209 300 748 1,540 2,248 1,372 1,278 1,454
Interest & Investment Income		 110 372 151 260 954 195 474 344
Other Income / (Expense), net		 -14 -303 -392 -224 0.69 -127 -65 43
Income Tax Expense		 250 287 -67 -980 -90 596 437 -604
Net Income / (Loss) Attributable to Noncontrolling Interest		 -5.14 1.67 1.01 -0.46 -1.50 -0.88 -0.16 -0.86
Basic Earnings per Share		 $147.15 $239.35 $140.61 $28.41 $240.72 $1.21 $1.54 $0.61
Weighted Average Basic Shares Outstanding		 - - 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B
Diluted Earnings per Share		 $146.26 $237.56 $139.82 $28.25 $238.96 $1.20 $1.52 $0.60
Weighted Average Diluted Shares Outstanding		 - - 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B
Weighted Average Basic & Diluted Shares Outstanding		 - - 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B

Quarterly Income Statements for Takeda Pharmaceutical

No quarterly income statements for Takeda Pharmaceutical are available.

Annual Cash Flow Statements for Takeda Pharmaceutical

This table details how cash moves in and out of Takeda Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024
Net Change in Cash & Equivalents		 -938 -392 3,943 -404 2,858 -1,196 -2,554 -674
Net Cash From Operating Activities		 2,346 3,555 -2,950 6,250 9,139 9,248 7,361 4,737
Net Cash From Continuing Operating Activities		 2,346 3,555 2,950 6,182 11,218 9,313 7,412 4,832
Net Income / (Loss) Continuing Operations		 1,037 1,757 1,213 413 3,401 1,895 2,388 954
Consolidated Net Income / (Loss)		 1,037 1,757 1,213 413 3,401 1,895 2,388 954
Depreciation Expense		 1,539 1,714 2,225 5,446 5,059 4,802 5,005 4,814
Non-Cash Adjustments To Reconcile Net Income		 -241 44 -36 2,325 1,837 2,023 1,842 2,143
Changes in Operating Assets and Liabilities, net		 11 41 -451 -2,003 922 593 -1,823 -3,079
Net Cash From Investing Activities		 -5,887 -878 -25,467 2,726 3,557 -1,631 -4,573 -3,067
Net Cash From Continuing Investing Activities		 -5,887 -878 -25,465 2,726 3,557 -1,631 -4,573 -2,847
Purchase of Property, Plant & Equipment		 -1,006 -1,207 -1,204 -2,032 -2,138 -1,532 -4,774 -3,179
Acquisitions		 -5,289 -267 -26,572 -46 0.00 -409 0.00 0.00
Purchase of Investments		 -109 -834 -154 -70 -114 -69 -76 -45
Sale of Property, Plant & Equipment		 24 28 455 117 420 15 7.25 57
Divestitures		 578 800 765 4,307 4,795 232 60 132
Sale and/or Maturity of Investments		 98 478 665 581 688 191 233 214
Other Investing Activities, net		 -183 122 577 -132 -93 -60 -23 -26
Net Cash From Financing Activities		 2,603 -3,069 26,460 -9,380 -9,839 -8,813 -5,342 -2,344
Net Cash From Continuing Financing Activities		 2,603 -3,069 26,460 -9,380 -9,839 -8,813 -5,342 -2,741
Repayment of Debt		 -1,820 -5,221 2,794 -11,286 -17,604 -7,889 -3,530 -3,147
Repurchase of Common Equity		 -208 -176 0.00 -35 -334 -638 -203 -15
Payment of Dividends		 -1,272 -1,335 -1,284 -2,637 -2,562 -2,336 -2,105 -1,899
Issuance of Debt		 5,990 3,702 25,110 4,630 10,663 2,053 565 2,493
Other Financing Activities, net		 -88 -38 -150 -52 -1.55 -3.17 -69 -173

Quarterly Cash Flow Statements for Takeda Pharmaceutical

No quarterly cash flow statements for Takeda Pharmaceutical are available.

Annual Balance Sheets for Takeda Pharmaceutical

This table presents Takeda Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024
Total Assets		 38,636 123,873 119,640 116,726 108,515 105,143 99,913
Total Current Assets		 10,150 26,880 23,044 24,524 21,357 18,064 16,920
Cash & Equivalents		 2,771 6,305 5,950 8,735 6,997 4,019 3,027
Accounts Receivable		 3,954 6,663 7,064 7,079 5,737 4,892 4,420
Inventories, net		 2,041 12,653 8,556 7,002 7,025 7,546 8,062
Current Deferred & Refundable Income Taxes		 80 65 260 268 228 243 193
Other Current Assets		 1,304 1,194 1,213 1,441 1,370 1,364 1,217
Plant, Property, & Equipment, net		 5,051 11,962 12,937 13,143 13,034 12,740 13,158
Plant, Property & Equipment, gross		 5,051 11,962 12,937 13,143 13,034 12,740 13,158
Total Noncurrent Assets		 23,435 85,030 83,660 79,058 74,124 74,339 69,835
Long-Term Investments		 1,016 972 1,002 3,149 2,718 2,854 2,848
Goodwill		 9,684 38,082 37,443 36,466 36,296 36,088 35,776
Intangible Assets		 9,543 42,670 38,925 35,338 31,444 32,163 28,268
Noncurrent Deferred & Refundable Income Taxes		 611 799 2,875 3,198 2,985 2,757 2,605
Other Noncurrent Operating Assets		 2,582 2,508 3,415 907 680 477 339
Total Liabilities & Shareholders' Equity		 38,636 123,873 119,640 116,726 108,515 105,143 99,913
Total Liabilities		 19,655 77,297 75,526 69,924 61,714 57,274 51,811
Total Current Liabilities		 6,939 22,929 20,304 16,029 17,669 18,696 15,296
Short-Term Debt		 0.17 8,846 5,476 200 1,680 2,558 2,429
Accounts Payable		 2,260 2,940 2,975 3,108 4,251 4,891 3,621
Current Deferred & Payable Income Tax Liabilities		 637 1,353 1,705 1,313 1,654 1,750 727
Other Current Liabilities		 3,763 9,365 9,255 11,408 10,083 9,497 8,520
Total Noncurrent Liabilities		 12,716 54,368 55,221 53,895 44,044 38,577 36,514
Long-Term Debt		 9,274 42,803 42,052 41,703 34,103 30,454 29,603
Noncurrent Deferred & Payable Income Tax Liabilities		 854 7,035 7,139 5,212 3,896 2,224 781
Noncurrent Employee Benefit Liabilities		 824 1,406 1,461 1,436 1,201 961 951
Other Noncurrent Operating Liabilities		 1,765 3,124 4,568 5,544 4,845 4,939 5,179
Total Equity & Noncontrolling Interests		 18,981 46,575 44,115 46,801 46,801 47,869 48,102
Total Preferred & Common Equity		 18,793 46,539 44,077 46,764 46,797 47,865 48,097
Preferred Stock		 854 14,821 15,680 15,263 14,072 13,023 11,555
Total Common Equity		 17,939 31,719 28,398 31,500 32,725 34,842 36,542
Common Stock		 733 14,761 15,566 15,080 13,803 12,628 11,087
Retained Earnings		 14,652 14,329 12,784 13,649 12,185 11,609 9,200
Treasury Stock		 -700 -513 -816 -538 -955 -756 -339
Other Equity Adjustments		 3,299 3,142 864 3,310 7,692 11,361 16,594
Noncontrolling Interest		 188 36 37 37 4.15 4.14 4.90

Quarterly Balance Sheets for Takeda Pharmaceutical

No quarterly balance sheets for Takeda Pharmaceutical are available.

Annual Metrics and Ratios for Takeda Pharmaceutical

This table displays calculated financial ratios and metrics derived from Takeda Pharmaceutical's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 7.13% 13.07% 63.06% -5.87% 1.66% 3.23% -7.06%
EBITDA Growth		 0.00% 26.02% 7.65% 55.25% 56.89% -12.35% 1.94% -27.36%
EBIT Growth		 0.00% 42.33% -11.62% -59.08% 545.67% -20.33% -1.05% -59.82%
NOPAT Growth		 0.00% 73.41% 15.55% -70.97% 620.97% -38.95% 8.19% 23.81%
Net Income Growth		 0.00% 69.39% -30.94% -65.93% 722.79% -44.26% 26.01% -60.07%
EPS Growth		 0.00% 62.42% -41.14% -79.80% 745.88% -99.50% 26.64% -60.37%
Operating Cash Flow Growth		 0.00% 51.51% -182.98% 311.85% 46.22% 1.20% -20.41% -35.64%
Free Cash Flow Firm Growth		 0.00% 0.00% -182.41% 110.01% 109.43% -49.31% -71.01% 82.42%
Invested Capital Growth		 0.00% 0.00% 269.23% -6.33% -10.24% -5.15% 1.56% 0.34%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - -
Gross Margin		 67.74% 71.99% 68.92% 66.89% 68.91% 68.99% 69.11% 66.54%
EBITDA Margin		 18.81% 22.12% 21.06% 20.06% 33.43% 28.82% 28.46% 22.25%
Operating Margin		 9.00% 13.66% 11.33% 3.05% 15.93% 12.91% 12.18% 5.02%
EBIT Margin		 8.91% 11.84% 9.25% 2.32% 15.93% 12.48% 11.96% 5.17%
Profit (Net Income) Margin		 6.67% 10.55% 6.44% 1.35% 11.76% 6.45% 7.87% 3.38%
Tax Burden Percent		 80.58% 85.96% 105.85% -72.90% 102.71% 76.07% 84.52% 273.15%
Interest Burden Percent		 92.89% 103.63% 65.76% -79.50% 71.90% 67.92% 77.84% 23.94%
Effective Tax Rate		 19.42% 14.04% -5.85% 0.00% -2.71% 23.93% 15.48% -173.15%
Return on Invested Capital (ROIC)		 0.00% 15.80% 3.89% 0.74% 5.82% 3.86% 4.25% 5.22%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 8.91% -0.25% 0.18% 2.11% 0.32% 1.44% -5.93%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 2.71% -0.19% 0.17% 1.66% 0.19% 0.79% -3.23%
Return on Equity (ROE)		 0.00% 18.51% 3.70% 0.91% 7.48% 4.05% 5.05% 1.99%
Cash Return on Invested Capital (CROIC)		 0.00% -184.20% -110.86% 7.28% 16.62% 9.14% 2.70% 4.88%
Operating Return on Assets (OROA)		 0.00% 5.10% 2.14% 0.59% 3.90% 3.26% 3.40% 1.42%
Return on Assets (ROA)		 0.00% 4.55% 1.49% 0.34% 2.88% 1.68% 2.24% 0.93%
Return on Common Equity (ROCE)		 0.00% 17.49% 2.80% 0.60% 4.93% 2.78% 3.60% 1.48%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 9.35% 2.61% 0.94% 7.27% 4.05% 4.99% 1.98%
Net Operating Profit after Tax (NOPAT)		 1,128 1,955 2,260 656 4,729 2,887 3,123 3,867
NOPAT Margin		 7.25% 11.74% 12.00% 2.14% 16.36% 9.82% 10.29% 13.71%
Net Nonoperating Expense Percent (NNEP)		 0.00% 6.90% 4.14% 0.56% 3.72% 3.54% 2.82% 11.14%
Cost of Revenue to Revenue		 32.26% 28.01% 31.08% 33.11% 31.09% 31.01% 30.89% 33.46%
SG&A Expenses to Revenue		 35.74% 35.48% 34.22% 29.31% 27.38% 24.84% 24.76% 24.72%
R&D to Revenue		 18.03% 18.38% 17.56% 14.96% 14.25% 14.74% 15.73% 17.12%
Operating Expenses to Revenue		 58.74% 58.33% 57.59% 63.84% 52.98% 56.07% 56.93% 61.52%
Earnings before Interest and Taxes (EBIT)		 1,385 1,972 1,743 713 4,604 3,668 3,630 1,458
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2,925 3,685 3,967 6,159 9,664 8,470 8,635 6,273
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.80 0.90 0.75 0.79 0.64
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.74 0.98 0.84 0.91 0.83
Price to Earnings (P/E)		 0.00 0.00 0.00 55.02 8.37 13.01 11.50 24.70
Dividend Yield		 0.00% 0.00% 2.25% 5.72% 4.58% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 1.82% 11.95% 7.69% 8.70% 4.05%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.92 0.96 0.89 0.90 0.82
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 2.57 2.55 2.20 2.20 2.17
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 12.83 7.63 7.65 7.72 9.76
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 110.79 16.02 17.66 18.35 42.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 120.46 15.60 22.44 21.33 15.84
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 12.64 8.07 7.00 9.05 12.93
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 12.26 5.47 9.47 33.60 16.93
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.49 1.11 1.08 0.90 0.76 0.69 0.67
Long-Term Debt to Equity		 0.00 0.49 0.92 0.95 0.89 0.73 0.64 0.62
Financial Leverage		 0.00 0.30 0.77 0.95 0.79 0.60 0.55 0.54
Leverage Ratio		 0.00 2.04 2.48 2.69 2.60 2.41 2.26 2.14
Compound Leverage Factor		 0.00 2.11 1.63 -2.13 1.87 1.63 1.76 0.51
Debt to Total Capital		 0.00% 32.82% 52.58% 51.86% 47.24% 43.33% 40.82% 39.97%
Short-Term Debt to Total Capital		 0.00% 0.00% 9.01% 5.98% 0.23% 2.03% 3.16% 3.03%
Long-Term Debt to Total Capital		 0.00% 32.82% 43.58% 45.89% 47.01% 41.29% 37.65% 36.94%
Preferred Equity to Total Capital		 0.00% 3.02% 15.09% 17.11% 17.21% 17.04% 16.10% 14.42%
Noncontrolling Interests to Total Capital		 0.00% 0.67% 0.04% 0.04% 0.04% 0.01% 0.01% 0.01%
Common Equity to Total Capital		 0.00% 63.49% 32.29% 30.99% 35.51% 39.63% 43.08% 45.60%
Debt to EBITDA		 0.00 2.52 13.02 7.72 4.34 4.22 3.82 5.11
Net Debt to EBITDA		 0.00 1.49 11.18 6.59 3.11 3.08 3.03 4.17
Long-Term Debt to EBITDA		 0.00 2.52 10.79 6.83 4.32 4.03 3.53 4.72
Debt to NOPAT		 0.00 4.74 22.86 72.47 8.86 12.40 10.57 8.28
Net Debt to NOPAT		 0.00 2.81 19.64 61.87 6.35 9.03 8.37 6.76
Long-Term Debt to NOPAT		 0.00 4.74 18.94 64.12 8.82 11.81 9.75 7.66
Altman Z-Score		 0.00 0.00 0.00 0.63 0.87 0.82 0.84 0.75
Noncontrolling Interest Sharing Ratio		 0.00% 5.49% 24.25% 33.71% 34.12% 31.38% 28.63% 25.62%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 1.46 1.17 1.13 1.53 1.21 0.97 1.11
Quick Ratio		 0.00 0.97 0.57 0.64 0.99 0.72 0.48 0.49
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -22,791 -64,365 6,442 13,493 6,839 1,983 3,617
Operating Cash Flow to CapEx		 238.91% 301.57% -393.87% 326.50% 532.03% 609.65% 154.44% 151.73%
Free Cash Flow to Firm to Interest Expense		 0.00 -75.87 -86.05 4.18 6.00 4.99 1.55 2.49
Operating Cash Flow to Interest Expense		 11.24 11.83 -3.94 4.06 4.07 6.74 5.76 3.26
Operating Cash Flow Less CapEx to Interest Expense		 6.54 7.91 -4.95 2.82 3.30 5.64 2.03 1.11
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.43 0.23 0.25 0.24 0.26 0.28 0.28
Accounts Receivable Turnover		 0.00 4.21 3.55 4.47 4.09 4.59 5.71 6.06
Inventory Turnover		 0.00 2.29 0.80 0.96 1.16 1.30 1.29 1.21
Fixed Asset Turnover		 0.00 3.30 2.21 2.47 2.22 2.25 2.35 2.18
Accounts Payable Turnover		 0.00 2.06 2.25 3.44 2.96 2.48 2.05 2.22
Days Sales Outstanding (DSO)		 0.00 86.64 102.87 81.57 89.29 79.58 63.94 60.27
Days Inventory Outstanding (DIO)		 0.00 159.67 458.16 380.63 315.89 280.88 283.76 301.92
Days Payable Outstanding (DPO)		 0.00 176.83 162.16 106.16 123.51 147.37 178.03 164.64
Cash Conversion Cycle (CCC)		 0.00 69.47 398.87 356.04 281.66 213.09 169.66 197.56
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 24,747 91,371 85,585 76,821 72,868 74,008 74,258
Invested Capital Turnover		 0.00 1.35 0.32 0.35 0.36 0.39 0.41 0.38
Increase / (Decrease) in Invested Capital		 0.00 24,747 66,625 -5,787 -8,764 -3,953 1,140 250
Enterprise Value (EV)		 0.00 0.00 0.00 79,009 73,765 64,780 66,624 61,249
Market Capitalization		 0.00 0.00 0.00 22,715 28,445 24,637 27,457 23,532
Book Value per Share		 $0.00 $0.00 $20.27 $18.15 $20.22 $19.02 $20.91 $21.57
Tangible Book Value per Share		 $0.00 $0.00 ($31.33) ($30.65) ($25.87) ($20.35) ($20.05) ($16.23)
Total Capital		 0.00 28,255 98,224 91,643 88,704 82,583 80,881 80,133
Total Debt		 0.00 9,274 51,649 47,528 41,903 35,782 33,012 32,031
Total Long-Term Debt		 0.00 9,274 42,803 42,052 41,703 34,103 30,454 29,603
Net Debt		 0.00 5,487 44,372 40,577 30,020 26,067 26,139 26,156
Capital Expenditures (CapEx)		 982 1,179 749 1,914 1,718 1,517 4,766 3,122
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 440 6,492 2,265 -39 -1,629 -2,094 1,025
Debt-free Net Working Capital (DFNWC)		 0.00 3,211 12,797 8,215 8,695 5,368 1,926 4,052
Net Working Capital (NWC)		 0.00 3,211 3,952 2,739 8,495 3,688 -633 1,623
Net Nonoperating Expense (NNE)		 91 199 1,046 243 1,328 991 735 2,913
Net Nonoperating Obligations (NNO)		 0.00 5,766 44,796 41,470 30,020 26,067 26,139 26,156
Total Depreciation and Amortization (D&A)		 1,539 1,714 2,225 5,446 5,059 4,802 5,005 4,814
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 2.64% 34.47% 7.38% -0.14% -5.54% -6.90% 3.63%
Debt-free Net Working Capital to Revenue		 0.00% 19.28% 67.94% 26.75% 30.08% 18.27% 6.35% 14.37%
Net Working Capital to Revenue		 0.00% 19.28% 20.98% 8.92% 29.39% 12.55% -2.09% 5.76%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $113.50 $28.41 $240.72 $147.14 $204.29 $0.61
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $112.86 $28.25 $238.96 $145.87 $201.94 $0.60
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B
Normalized Net Operating Profit after Tax (NOPAT)		 1,655 2,979 2,143 2,280 4,861 3,883 4,048 1,947
Normalized NOPAT Margin		 10.64% 17.88% 11.38% 7.43% 16.82% 13.21% 13.34% 6.91%
Pre Tax Income Margin		 8.28% 12.27% 6.08% -1.85% 11.45% 8.48% 9.31% 1.24%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 6.64 6.56 2.33 0.46 2.05 2.67 2.84 1.00
NOPAT to Interest Expense		 5.40 6.51 3.02 0.43 2.10 2.10 2.44 2.66
EBIT Less CapEx to Interest Expense		 1.93 2.64 1.33 -0.78 1.28 1.57 -0.89 -1.14
NOPAT Less CapEx to Interest Expense		 0.70 2.59 2.02 -0.82 1.34 1.00 -1.29 0.51
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 122.66% 76.00% 105.83% 638.03% 75.33% 123.24% 88.13% 199.16%
Augmented Payout Ratio		 142.67% 86.04% 105.83% 646.46% 85.15% 156.93% 96.63% 200.78%

Quarterly Metrics and Ratios for Takeda Pharmaceutical

No quarterly metrics and ratios for Takeda Pharmaceutical are available.

Frequently Asked Questions About Takeda Pharmaceutical's Financials

When does Takeda Pharmaceutical's financial year end?

According to the most recent income statement we have on file, Takeda Pharmaceutical's fiscal year ends in March. Their fiscal year 2024 ended on March 31, 2024.

How has Takeda Pharmaceutical's net income changed over the last 7 years?

Takeda Pharmaceutical's net income appears to be on an upward trend, with a most recent value of $953.56 million in 2024, falling from $1.04 billion in 2017. The previous period was $2.39 billion in 2023. See Takeda Pharmaceutical's forecast for analyst expectations on what’s next for the company.

What is Takeda Pharmaceutical's operating income?
Takeda Pharmaceutical's total operating income in 2024 was $1.42 billion, based on the following breakdown:
  • Total Gross Profit: $18.76 billion
  • Total Operating Expenses: $17.35 billion
How has Takeda Pharmaceutical revenue changed over the last 7 years?

Over the last 7 years, Takeda Pharmaceutical's total revenue changed from $15.55 billion in 2017 to $28.20 billion in 2024, a change of 81.3%.

How much debt does Takeda Pharmaceutical have?

Takeda Pharmaceutical's total liabilities were at $51.81 billion at the end of 2024, a 9.5% decrease from 2023, and a 163.6% increase since 2018.

How much cash does Takeda Pharmaceutical have?

In the past 6 years, Takeda Pharmaceutical's cash and equivalents has ranged from $2.77 billion in 2018 to $8.73 billion in 2021, and is currently $3.03 billion as of their latest financial filing in 2024.

How has Takeda Pharmaceutical's book value per share changed over the last 7 years?

Over the last 7 years, Takeda Pharmaceutical's book value per share changed from 0.00 in 2017 to 21.57 in 2024, a change of 2,156.9%.


Related Companies

This page (NYSE:TAK) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
REVEALED: Elon’s Secret Master Plan “AGENDA X”
REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...
Brownstone Research | Sponsored
Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Trump's $500B plan is fueling these monthly dividends
Something extraordinary happened just 24 hours after Trump returned to office... He signed a document that ...
Investors Alley | Sponsored
Confidential Economic Advisory
I've hesitated for months to record this video. The very act of sharing these details makes me deeply uncom...
InvestorPlace | Sponsored
The New Elon
The New Face of DOGE? There is now a new, powerful and controversial figure at the heart of the DOGE agenda...
Altimetry | Sponsored
Our #1 Defense Stock for May
We've already lost 18 straight simulated war games against China. The good news is, the U.S. military has a...
Behind the Markets | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored